Thursday, January 20, 2022 12:42:07 PM
ATLnsider,
You may be right but I don’t think FDA wants to underestimate demand from all comers including project Orbis (expanding) off label etc and that requires a much more aggressive ramp capability. That capability is what flipper44 and I believe must be in place at or just after news which will create instant demand for availability. A breakthrough has no where to hide once news is out. Linda has done a great job of hiding until ready so as to defend against creating false patient hope when they can’t access the treatment yet. With Charles River Labs adding two new large clean room suites in their Pennsylvania facility last year with additional equipment installed to increase output for a “vaccine candidate”(sounds like a comparability test drive) I believe bears and some longs are not taking this very important aspect into full consideration. Anyway just my two copper coins worth ; ). Best wishes.
You may be right but I don’t think FDA wants to underestimate demand from all comers including project Orbis (expanding) off label etc and that requires a much more aggressive ramp capability. That capability is what flipper44 and I believe must be in place at or just after news which will create instant demand for availability. A breakthrough has no where to hide once news is out. Linda has done a great job of hiding until ready so as to defend against creating false patient hope when they can’t access the treatment yet. With Charles River Labs adding two new large clean room suites in their Pennsylvania facility last year with additional equipment installed to increase output for a “vaccine candidate”(sounds like a comparability test drive) I believe bears and some longs are not taking this very important aspect into full consideration. Anyway just my two copper coins worth ; ). Best wishes.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
